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Background: Cortical thickness measures the width of gray matter of the human cortex. It can be calculated from 
T1-weighted magnetic resonance images (MRI). In group studies, this measure has been shown to correlate with 
the diagnosis/prognosis of a number of neurologic and psychiatric conditions, but has not been widely adapted for 
clinical routine. One of the reasons for this might be that there is no reference system which allows to rate individual 
cortical thickness data with respect to a control population.
Methods: To address this problem, this study compared different methods to assess statistical significance of cortical 
thinning, i.e. atrophy. All compared methods were nonparametric and encompassed rating an individual subject’s 
data set with respect to a control data population. Null distributions were calculated using data from the Human 
Connectome Project (HCP, n = 1000), and an additional HCP data set (n = 113) was used to calculate sensitivity and 
specificity to compare the different methods, whereas atrophy was simulated for sensitivity assessment. Validation 
measures were calculated for the entire cortex (“cumulative”) and distinct brain regions (“regional”) where possible.
Results: The approach yielding the highest combination of specificity and sensitivity implemented generating null 
distributions for anatomically distinct brain regions, based on the most extreme values observed in the population. 
With that method, while regional variations were observed, cumulative specificity of 98.9% and cumulative sensitivity 
at 80% was achieved for simulated atrophy of 23%.
Conclusions: This study shows that validated rating of individual cortical thickness measures is possible, which can 
help clinicians in their daily routine to discover signs of atrophy before they become visually apparent on an unpro-
cessed MRI. Furthermore, given different pathologies present with distinct atrophy patterns, the regional valida-
tion proposed here allows to detect distinct patterns of atrophy, which can further enhance differential diagnosis/
prognosis.
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Background
Using magnetic resonance imaging (MRI), images with 
high-tissue contrast [1] of the brain can be acquired with-
out making use of radioactive contamination of patients. 
Beyond clinical applications, MRI has been widely used 
for neuroscientific studies. Constantly, methods are being 
developed which allow to quantify biologic character-
istics of the central nervous system and its constituents 
more and more differentiated, encompassing blood flow, 
nerve fiber myelination and properties of the cortex or 
“gray matter” (GM). The GM is the location of the neu-
ron bodies, whereas the extent of cortical thickness 
seems to be related to synaptic density, synaptic pruning 
and intracranial myelination [2–5], rather than the num-
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sufficient to compute cortical thickness in an automated 
procedure and can be further optimized with an addi-
tional T2-weighted image [7, 8]. Common algorithms 
to calculate cortical thickness are publicly available, e.g. 
under the open-source software package FreeSurfer [9].
Cortical thickness has been subject to a wide range 
of studies, and cortical thinning (i.e. atrophy) has been 
associated with diagnosis and progression of a number 
of neurologic conditions, such as Alzheimer’s Disease 
[10], Parkinson’s Disease [11] and Multiple Sclerosis [12] 
as well as psychiatric conditions, such as depression [13] 
and schizophrenia [14]. Interestingly, such pathological 
conditions present with different patterns of cortical thin-
ning and are modified by age and genetic components 
[15, 16]. These specific aspects make cortical thickness a 
good candidate as a biomarker for differential diagnosis/
prognosis. However assessing cortical thickness is rarely 
incorporated in clinical practice. One of the reasons for 
this might be the lack of a standardized system, based on 
which an individual’s cortical thickness data can be rated. 
To pass this limit, the present study aimed to develop a 
method to rate an individual’s cortical thickness data 
with respect to a control population which detects corti-
cal atrophy with high sensitivity and specificity. To allow 
detecting distinct patterns of cortical atrophy, the tested 
methods allow the evaluation of separate brain regions. 
Such a standardized procedure can help clinicians detect 




In order to rate an individual’s data with respect to a 
control population, a large number of standardized data 
from a representative population sample is required. 
The Human Connectome Project (HCP) provides such 
a resource [17–19]. For this study, data from the HCP’s 
1200 Subject Release was used. In total, structural data 
(T1- and T2-weighted sequences) from 1113 subjects 
was available at the time of this study (507 males, aged 
between 22 and  40). Of the 1113 subjects, 1000 were 
randomly selected for generating null distributions of 
cortical thickness, the rest was spared for subsequent val-
idation (see below).
Data acquisition and preprocessing
The HCP data was acquired on a 3 Tesla Connec-
tome Scanner. Two different types of structural ses-
sions were acquired, encompassing a T1-weighted 
MPRAGE (repetition time (TR) = 2400  ms, echo time 
(TE) = 2.14  ms, inversion time = 1000  ms, flip angle 
(FA) = 8°, field of view (FOV) = 224 × 224, voxel reso-
lution (VR) = 0.7  mm3, bandwidth (BW) = 210  Hz/Px, 
iPAT factor 2, total acquisition time 7  min 40  s) and a 
T2-weighted SPACE (TR = 3200  ms, TE = 565  ms, FA 
variable, FOV = 224 × 224, VR = 0.7 mm3, BW = 744 Hz/
Px, iPAT factor 2, total acquisition time 8 min 24 s). The 
full imaging protocols can be found online at http://proto 
cols.human conne ctome .org/HCP/3T/imagi ng-proto cols.
html. All study procedures of the HCP protocol were 
approved by the Institutional Review Board at the Wash-
ington University in St. Louis.
The HCP offers data which was preprocessed with 
standardized and validated procedures. The main pre-
processing steps encompassed gradient distortion cor-
rection, brain extraction, nonlinear registration, surface 
registration, and registration onto high-resolution (164 k 
mesh) and low-resolution (32  k mesh) templates; more 
details on the exact preprocessing pipeline can be found 
in [9, 20–22]. The image format of the mesh images is 
in CIFTI format (Connectivity Informatics Technology 
Initiative), a file format which combines surface-based 
cortical data with volumetric-based subcortical/cerebel-
lar data, which was found to enhance alignment to the 
geometry of the cortex as well as statistical power [23]. 
The HCP’s minimally preprocessed data include corti-
cal thickness maps (generated based on the standardized 
FreeSurfer pipeline with combined T1-/T2-reconstruc-
tion [7, 8]). For this study, the high-resolution cortical 
thickness maps (164 k mesh) were used.
Statistical analysis
Statistical analysis of the minimally preprocessed HCP 
neuroimaging data was carried out with tools from the 
Connectome Workbench [18, 19] and MATLAB R2019b 
(The Mathworks, Natick, USA). First, null distribu-
tions were generated using different strategies and sub-
sequently, these methods were validated and compared 
based on their specificity and sensitivity.
Generating null distributions
Different strategies to generate null distributions were 
compared. These can be subdivided into (a) generat-
ing one common null distribution for all data points on 
the cortex (referred to as “vertices” in CIFTI mesh files) 
and (b) generating separate null distributions for distinct 
brain regions (Fig.  1a, b). Note that thickness spreads 
nonuniformly across the human cortex [24–27] such that 
different brain regions show different population means 
(Fig.  1c). Therefore, different null distributions for dis-
tinct brain regions might increase sensitivity of detecting 
atrophy, which is why both approaches were compared in 
the present study. The two approaches were subdivided 
further into more and less conservative statistical correc-
tions, such that in total, four methods were compared. 
Null distributions were computed using nonparametric 
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permutation procedures for all methods [28], since they 
make less assumptions than parametric models and are 
therefore considered more robust than parametric tests 
[29, 30].
Method 1: Z‑min statistic per data point The statistically 
most conservative approach was based on generating one 
common reference distribution for all 298,261 data points 
of the cortical surface. First, from 1000 HCP data sets, 
each data set was selected iteratively (“test data set”) and 
standardized with respect to the remaining 999 data sets 
(“control data sets”). For that, z-scores were calculated for 
each vertex using the formula  zvertex = (dvertex – μvertex)/
σvertex, whereas  dvertex is the cortical thickness value of one 
vertex from the test data set, μvertex the mean value of that 
vertex from the control data sets and σvertex the respec-
tive standard deviation. From the resulting z-score map, 
only the minimum value was saved (note that the present 
research question specifically addresses cortical thinning). 
The result was a reference distribution consisting of 1000 
z-scores. Using this distribution, each vertex of an inde-
pendent validation data set can be rated separately with 
respect to the reference population, by z-transforming 
each vertex using the above formula (see section “Valida-
tion”).
Method 2: Z‑min statistic per  data point, averaged 
across brain regions In method 1, a null distribution was 
calculated based on the most extreme values across the 
cortex. However, given that cortical thickness is nonuni-
formly distributed across the cortex physiologically [27], 
potential atrophy will be hard to detect in physiologi-
cally thicker brain regions. Method 2 aimed to increase 
the biological plausibility of the previous method. While 
the same null distribution was used as in method 1, in 
method 2, data points were summarized across anatomi-
cally distinct brain regions, defined by the Desikan–Kil-
liany atlas [31]. This atlas subdivides the cortical surface 
into 68 regions based on morphologic features (“labels”, 
34 on each hemisphere). For subsequent validation, sta-
Fig. 1 Generating a reference system for rating an individual’s 
cortical thickness data with respect to a control population. In 
methods 3 and 4, each cortical thickness map from a population 
sample (a) was divided into 68 distinct brain regions (borders are 
indicated as black lines in b). Given that the different brain regions 
have different means and standard deviations (c), this approach is 
biologically more plausible than generating one common reference 
system for all brain regions (as was tested here in methods 1 and 2). 
Based on these null distributions (see d for an example), the observed 
values for an individual can be rated within the control population 
(see red line in e) and statistically significant cortical thinning (i.e. 
atrophy) can be assessed
▸
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tistical significance was determined for the synopsis of all 
vertices within each of the 68 regions, instead of for each 
vertex separately (see section “Validation”).
Method 3: Z‑min statistic per brain region In spite of the 
increased biological plausibility in method 2, that pro-
cedure was still based on one common null distribution 
from the most extreme values of the cortex. In method 
3, this was corrected by calculating distinct null distribu-
tions for each of the 68 Desikan–Killiany-labels. For that, 
the permutation procedure described in method 1 was 
repeated, however now z-maps were calculated using the 
formula  zvertex = (dvertex – μLabel)/σLabel, whereas  zvertex was 
the z-score for a vertex of the test data set,  dvertex is the 
observed cortical thickness value for that vertex from the 
test data set, μLabel is the mean value of the respective label 
from the control data sets and σLabel its respective stand-
ard deviation. On each iteration, the minimum z-score 
of all vertices composing one common label was saved, 
such that the result was a 68x1000 matrix, providing a 
null distribution for each label (Fig. 1d). With these null 
distributions, each brain region can be rated separately 
with respect to the reference population, by converting 
the cortical thickness data into z-scores using the formula 
 zLabel = (dLabel – μLabel)/σLabel (Fig. 1e).
Method 4: Z‑score per  brain region Finally, in method 
4, null distributions were generated based on averaging 
across all vertices from each brain region instead of using 
each label’s most extreme values, as in method 3. Mean 
values were calculated for each brain region of the test 
data set to derive null distributions. These null distribu-
tions were generated in analogy to method 3, using the 
formula  zLabel = (dLabel – μLabel)/σLabel. Similar to method 
3, also in method 4, each brain region can be rated sepa-
rately with respect to the reference population, by con-
verting the cortical thickness data into z-scores using the 
formula  zLabel = (dLabel – μLabel)/σLabel.
Validation
To validate and compare the proposed methods, speci-
ficity and sensitivity were calculated. These measures 
were calculated for each vertex (method 1) or each label 
(methods 2–4) separately. For that, the 113 data sets 
(“validation data sets”) from the 1113 HCP data sets 
were used which had been spared for the generation of 
null distributions (see section “Subjects”). Statistical 
inference tests based on the null hypothesis of no atro-
phy for a given validation data set were carried out using 
the above-generated null distributions. For each vertex/
label, the number of values of the null distributions that 
were lower than the observed cortical thickness values 
in a given validation data set were counted. Dividing this 
sum by the number of permutations (n = 1000) yielded 
FWER-corrected p-values  (pFWER) [32, 33]. Vertices/
labels with  pFWER <= 0.05 were considered to indicate 
lower cortical thickness values than would not be pre-
dicted by chance and therefore labeled as “atrophic”. In 
method 2, since data points were summarized within 
each label, a label was defined as “atrophic” if a certain 
percentage of its vertices showed  pFWER <= 0.05. Differ-
ent percentages were tested (1%, 5%, 10%, 20%, 30%, 40%, 
50%). Given that all of these thresholds yielded similarly 
poor results, hereafter only the results for one threshold 
(5%, arbitrary choice) are provided. The data for the other 
thresholds are provided in Additional files 1 and 2.
Specificity Specificity defines the rate of true negatives, 
i.e. the share of patients which are correctly diagnosed as 
not having the condition of interest (here, “no atrophy”). 
The validation data set was used to calculate specificity, 
assuming that—given this data set was a random selec-
tion of a data set of healthy young subjects with no his-
tory of psychiatric/neurologic disorders—the validation 
data set can be labeled as non-atrophic. Each of the four 
methods was applied to all of the 113 validation data sets 
and specificity was defined as the percentage of vertices 
(method 1)/labels (methods 2, 3, 4) which were not classi-
fied as significantly atrophic. This procedure was repeated 
for each validation data set separately. Mean and standard 
deviations of the specificity calculations were determined 
across all 113 data sets (“cumulative specificity”).
To allow evaluation for distinct brain regions, in addi-
tion, specificity per atlas region was defined (for methods 
2,3 and 4 only, since in method 1, no atlas regions were 
analyzed). This was done by calculating, per atlas region, 
the percentage of the 113 validation data sets which were 
not significantly classified as atrophic in that atlas region 
(“regional specificity”).
Sensitivity Sensitivity defines the rate of true positives, 
i.e. the share of patients which are correctly diagnosed as 
having the condition of interest (here, “atrophy”). Given 
no true atrophy was assumed in the validation data sets, 
atrophy was simulated: Different degrees of atrophy 
were simulated as follows (Fig.  2): The original cortical 
thickness data (each vertex) was multiplied by a number 
between 0 and 1 (e.g. multiplication by 0.9 represents 
simulated atrophy of 10%, etc.). For each of the 113 vali-
dation data sets, atrophy was simulated from 1% to 100% 
in steps of 1 percentage points (p.p.). Then, each of the 
four methods was applied to all of the simulated data sets. 
For each method and degree of atrophy, sensitivity was 
calculated separately. Cumulative sensitivity was defined 
as the percentage of vertices (method 1) or labels (meth-
ods 2, 3, 4) which were classified as significantly atrophic, 
Page 5 of 12Tahedl  J Transl Med          (2020) 18:151  
summarized across all 113 data sets (“cumulative sensi-
tivity”). Sensitivity across methods was compared using 
the degree of atrophy required to achieve cumulative sen-
sitivity of 80% (“cumulative sensitivity threshold”). Note 
that less sensitive methods will require more pronounced 
atrophy, therefore a higher cumulative sensitivity thresh-
old, in order to detect atrophy.
To allow evaluation for distinct brain regions, addi-
tionally, sensitivity per atlas region was defined for each 
degree of atrophy (for methods 2,3 and 4 only, since in 
method 1, no atlas regions were analyzed). This was done 
by calculating, per atlas region, the percentage of the 113 
validation data sets which were significantly classified as 
atrophic in that atlas region (“regional sensitivity”).
Note that although cortical thickness was simulated 
at consistent rates throughout the cortex (which is not 
how cortical thinning occurs in aging or pathology [10, 
15, 16]), evaluation was performed for each vertex/label 
independently. Therefore, the proposed methods are fit 
to analyze also diffuse patterns of cortical thinning.
Results
Specificity
Table  1 summarizes the cumulative specificity calcula-
tions for each method. Methods 1 and 2 showed ideal 
specificity (100%, ± 0 p.p.), such that these methods clas-
sified no vertex (method 1)/label (method 2) as signifi-
cantly atrophic. Method 3 had a mean specificity of 98.9% 
(± 1.3 p.p.), and method 4 was less specific with a mean 
of 93.6% (± 2.0 p.p.). Figure 3 shows the regional specific-
ity profiles evaluated across all 68 atlas regions. While the 
most specific method (method 2, red dashed line) yielded 
100% specificity for each label, method 3 showed rela-
tively constant specificity across brain regions except for 
a slight drop for the right lingual gyrus. Method 3 showed 
specificity of 100% for almost all labels on the right hemi-
sphere (notice however a slight drop for the right lingual 
gyrus), while the values were slightly lower for the labels 
on the left hemisphere. Finally, method 4 (golden dashed 
line) showed notably lower values throughout all labels as 
compared to methods 2 and 3.
Fig. 2 Atrophy was simulated for sensitivity calculations as follows: The original cortical thickness map from each of the subjects from the control 
population (“0% atrophy”) was multiplied by values ranging between 0 and 1. Multiplication by lower values indicate higher degrees of simulated 
atrophy. For example, multiplication by 0.9 simulates 10% atrophy, multiplication by 0.8 20% atrophy, etc. In the present study, atrophy was 
simulated between 1% and 100% in steps of one percentage points. This allows to assess sensitivity by the degree of simulated atrophy. In this 
Figure, coloring indicates cortical thickness in millimeters
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Sensitivity
Figure 4 illustrates the cumulative sensitivity profiles for 
each method relative to the degree of simulated atro-
phy. The horizontal dashed line denotes sensitivity at 
80% (cumulative sensitivity threshold), which was used 
to compare the different methods. Table  2 summarizes 
these results: Method 1 (red line) was extremely unsensi-
tive, such that not even for the highest possible degree of 
atrophy (literally no brain) did this method detect atro-
phy in 80% of cases (i.e. cumulative sensitivity threshold 
not reached). Method 2 (blue line) yielded a cumulative 
sensitivity threshold for 88% simulated atrophy when 
a label was considered atrophic if 5% of its vertices had 
 pFWER < 0.05 (see “Methods”). Other tested thresholds for 
method 2 comprised 1% (cumulative sensitivity threshold 
for 84% simulated atrophy), 10% (90% atrophy), 20% (94% 
atrophy), 30% (98% atrophy), 40%/50% (did not reach 
80% sensitivity for any degree of simulated atrophy, see 
Additional file 1: Fig. S1 and Additional file 2: Table S1). 
Method 3 (yellow line) was clearly superior (cumulative 
sensitivity threshold 23% simulated atrophy), and for 
method 4 an even lower value (12% simulated atrophy) 
was observed. 
Figure  5 shows the results of the regional sensitivity 
determination for methods 2 (Fig. 5a), 3 (Fig. 5b) and 4 
(Fig.  5c). To compare the methods, the regional sensi-
tivity profiles are plotted for each method’s cumulative 
sensitivity threshold (i.e. 88% atrophy for method 2: blue 
lines, 23% atrophy for method 3: red lines, 12% atrophy 
for method 4: golden lines). To enhance orientation, 80% 
sensitivity is indicated with a gray dashed line in Fig. 5a–
c. Additionally, regional specificity for each method is 
plotted (red dashed lines).
Figure 5a illustrates poor sensitivity of method 2, given 
it reaches sensitivity of > 0% for none of the cumulative 
sensitivity thresholds of the other methods. Additionally, 
the regional sensitivity profile for its own cumulative sen-
sitivity threshold (88% simulated atrophy) shows strong 
variations across labels. Method 3 (Fig.  5b) is clearly 
superior: while the variations for its own cumulative 
Fig. 3 Comparison of regional specificity profiles between methods 2–4. The statistically most conservative approach (method 2, “z-min: per data 
point, averaged across labels”, red dashed line) yielded ideal specificity for all brain regions, i.e. it correctly assigns “no atrophy” in 100% of cases. The 
less conservative method 3 (“z-min: per label”, purple dashed line) also showed specificity of 100% for many brain regions, but had some drops, 
e.g. for the right lingual gyrus. The most liberal approach, method 4 (“z-score: per label”, golden dashed line) yielded lower specificity for all brain 
regions. Note that method 1 (“z-min: per data point”) is not shown here because it does not allow for labelwise assessment. See also Table 1 for the 
cumulative specificity values for each method
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Fig. 4 Cumulative sensitivity relative to the degree of simulated atrophy (across vertices/brain regions), comparison between the four tested 
methods. All methods detected atrophy more sensitive for more pronounced degrees of atrophy. However, the degree of atrophy the methods 
required to reach a given level of sensitivity differed. For example, in the current simulation, in order to detect atrophy in 80% of cases (black 
horizontal dashed line), method 4 (“z-score: per label”, purple line) required only 12% atrophy, method 3 (“z-min: per label”, golden line) 23%, 
method 2 (“z-min: per data point, averaged across labels”, blue line) 88%, while method 1 (“z-min: per data point”, red line) failed to detect atrophy in 
80% of cases even for the highest possible degree of atrophy (100%). Compare also Table 2 for a summary of these results
Table 2 Cumulative sensitivity thresholds for the four tested methods
* Note that lower values of atrophy suggest more sensitive methods, since they detect less pronounced atrophy
Method 1 (“z-min: per data 
point”)
Method 2 (“z-min: 
per data point, averaged 
across labels”)
Method 3 (“z-min: 
per label”)
Method 4 (“z-score: 
per label”)
Degree of atrophy required 
for detection of atrophy in 
80% of cases (cumulative 
sensitivity threshold)*
Not available 88% 23% 12%
(See figure on next page.)
Fig. 5 Regional sensitivity (per brain region) for each region’s cumulative sensitivity threshold (i.e. the degree of atrophy each method required to 
detect atrophy in 80% of cases) for method 2 (a, “z-min: per data point, averaged across labels”, method 3 (b, “z-min: per label”) and method 4 (c, 
“z-score: per label”). The cumulative sensitivity threshold for method 2 was 88% atrophy (blue lines), for method 3 23% atrophy (red lines) and for 
method 4 12% atrophy (golden lines). The 80% sensitivity line is indicated by the gray dashed lines in each panel. In addition, regional specificity is 
plotted for each method (red dashed lines, compare also Fig. 3). All methods detected atrophy more sensitively for more pronounced degrees of 
atrophy
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sensitivity threshold (23% simulated atrophy) are less 
pronounced as compared to method 2, it yields per-
fect (i.e. 100%) sensitivity for the cumulative sensitivity 
threshold of method 2. However, no region reaches 80% 
sensitivity for the cumulative sensitivity threshold of 
method 3. Finally, method 4 (Fig. 5c) is the most sensitive 
of the tested methods. It yields almost perfect regional 
sensitivity for the cumulative sensitivity thresholds of 
methods 2 and 3, and the regional sensitivity profile for 
its own cumulative sensitivity threshold (12% simulated 
atrophy) shows less variations than the other methods. 
Note however the relatively low specificity (red dashed 
line) of this method as compared to the others.
Nevertheless, it is evident from Fig.  5 that there 
are regional variations for the cumulative sensitivity 
thresholds for each method. Additional file 3: Table S2 
lists the labels which show less regional sensitivity 
than 80% for each method and their  respective cumu-
lative sensitivity threshold. For example, for method 3, 
among the brain regions that yielded least sensitivity 
for that method’s cumulative sensitivity threshold (23% 
atrophy) are, on the left hemisphere, parahippocam-
pal gyrus (49.56% sensitivity), temporal pole (23.89% 
sensitivity), frontal pole (9.73% sensitivity), temporal 
pole (23.89% sensitivity) and transverse temporal gyrus 
(1.77% sensitivity), and on the right hemisphere, pars 
orbitalis (27.43% sensitivity), rostral anterior cingulate 
(24.78% sensitivity), frontal pole (29.20% sensitivity), 
temporal pole (6.19% sensitivity) and transverse tempo-
ral gyrus (23.89% sensitivity).
Discussion
The goal of this study was to develop a method which 
allows to rate a single patient’s cortical thickness data 
and identify atrophy sensitively and specifically with 
respect to a control population. This study was moti-
vated by the many previous reports which have found 
pronounced associations of cortical thinning with the 
diagnosis/progression of diverse neurological and psy-
chiatric conditions. In addition, given that different 
pathologies present with different patterns of cortical 
thinning, another goal was to allow the evaluation of 
cortical thinning for distinct brain regions. To provide 
such a resource, a reference system was developed by 
generating population-based distributions of expected 
cortical thickness data, both for the entire cortex as 
well as for distinct brain regions. 1000 data sets from 
young and healthy participants were used to generate 
expected population null distributions using a per-
mutation procedure. To assess statistically significant 
cortical thinning (i.e. atrophy), different methods were 
tested and compared using sensitivity and specific-
ity calculations for the entire cortex (“cumulative”) as 
well as for distinct brain regions (“regional”), calculated 
from 113 additional subjects. The statistically most 
stringent methods were based on one common null 
distribution for all brain regions, which showed ideal 
specificity but poor sensitivity. Other methods were 
based on distinct null distributions for different brain 
regions, which increased sensitivity but decreased 
specificity. However, when generating distinct null dis-
tributions for different brain regions based on the most 
extreme values within each label (method 3), the drop 
in cumulative specificity was only very subtle (98.9%), 
while cumulative sensitivity could still be detected at 
80% for 23% simulated atrophy. Variations of regional 
differences were observed for some brain regions, but 
decreased for more pronounced degrees of atrophy.
These results emphasize that in order to sensitively 
detect cortical atrophy for individual patients, it is rea-
sonable to create different null distributions for distinct 
brain regions. Cortical thickness is not spread uniformly 
across the cortex [34], such that for example neurite den-
sity is higher for motor regions as compared to regions 
associated with higher cognitive functions [27]. There-
fore, a single reference distribution to rate any cor-
tex region is biologically implausible and will result in 
decreases of sensitivity, which was shown here in meth-
ods 1 and 2. Furthermore, with this approach, sensitivity 
is relatively constant for different brain regions, although 
regional variations are observed (Fig. 5b).
One drawback of working with several null distribu-
tions for different brain regions as opposed to a com-
mon one is that specificity decreases, which was shown 
in methods 3 and 4. In method 3, a strategy was sug-
gested to minimize this loss in specificity while main-
taining a high level of sensitivity: The idea of method 
3 was to generate null distributions for different brain 
regions based on the (minimally) most extreme values 
within each brain region across a control population, 
instead of working with averages across brain regions. 
With this strategy, atrophy could be detected in 80% of 
cases when the cortex was roughly three quarters of its 
original thickness. However, in cases where the clini-
cian wishes to detect atrophy more sensitively, method 
4 might be preferred—there, null distributions were 
generated from population averages (rather than from 
their most extreme values). In this study, that method 
could detect atrophy in 80% of cases already when the 
cortex was thinned by a factor of only 12% (also here, 
regional variations were observed, see Fig.  5c). How-
ever, that approach would imply risking to detect false 
positives, given its lower specificity. Depending on the 
situation, the clinician can flexibly choose between 
more sensitivity or more specificity.
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One limitation of the suggested reference system is 
that it was generated from a relatively homogenous 
control population of healthy young adults. However, 
cortical thickness declines even in physiological aging, 
such that the comparison of an elderly individual to that 
reference group will result in more pronounced atro-
phy detection, which would not necessarily have to be 
pathologic [10, 15]. Nevertheless, given that the regions 
that exhibit cortical thinning differ in physiological 
and pathological aging (for example, atrophy of brain 
regions such as the precuneus and the inferior tempo-
ral region can be indicative of early signs of dementia 
[35]), it is still possible to detect such potential patho-
logic signatures using the method proposed here. This is 
possible because the reference system suggested herein 
was generated and evaluated for different brain regions 
separately. This allows to rate different brain regions 
independently, such that different atrophy patterns can 
be identified. Figure  6 illustrates this: For patient X, 
atrophy was simulated in frontal areas, for patient Y in 
more posterior regions. Using method 3, the resulting 
p-map indicates where cortical thinning occurred for 
that patient. Such maps can be generated easily with a 
given patient’s T1-weighted MRI using the procedure 
proposed here, and are therefore easy to implement into 
clinical practice.
The atlas used in this work was the Desikan–Killiany 
atlas, a brain atlas defined by morphologic features 
of the cortex and therefore surface-based. This is an 
important feature because cortical thinning is modified 
by genetic components [15, 16], and such genetic pat-
terns yield high resemblance to surface-based features 
[36]. Additionally, patterns of genetic overlap seem to be 
coarse-grained across the human cortex (current opti-
mal solutions suggest between 9 and 12 labels per hemi-
sphere [16, 36]), such that the Desikan–Killiany atlas 
(34 labels per hemisphere) allows a more fine-grained 
resolution than proposed by genetic commonalities. 
However, especially in early pathology, cortical thinning 
may be more localized, such that future work should 
investigate the benefit of using a more fine-grained atlas 
for such cases. Furthermore, a more fine-grained atlas 
might also help to enhance regional sensitivity of those 
brain regions which showed poor sensitivity with the 
Desikan–Killiany altas (such as the left frontal pole as 
well as the left and right transverse temporal gyri). The 
evaluation of these regions with the current method 
and atlas should be made with caution given their lower 
sensitivity.
Finally, the current reference system allows to pro-
gress-monitor an individual’s condition: given the com-
position of the reference standard does not change, any 
potential changes between two measurement time points 
can be more likely attributed to changes in the individual. 
Finally, it should be emphasized that atrophy was only 
simulated in this study, and it is subject to future work 
to validate the present simulations with real data. It will 
also be necessary to show that the system is applicable to 
data acquired from different types of MR scanners and 
sequence parameters (here, data from a 3 Tesla MR scan-
ner with optimized parameters for T1-weighted imaging 
were analyzed).
Conclusions
Taken together, the here suggested reference system 
can be used for sensitive and specific detection of cor-
tical atrophy for distinct brain regions (defined by the 
Desikan–Killiany atlas) for age groups comparable to 
the reference population (22–40  years), which allows to 
detect differential patterns of cortical thinning. However, 
some brain regions are detected less sensitively such that 
those regions should be evaluated with care. The method 
should therefore be further validated with data from dif-
ferent pathologies and using different atlases. Although 
distinct reference systems for different age groups will 
further help to establish this method in clinical practice, 
the current method already allows to rate elderly individ-
uals, however these cases should be treated with caution 
given the risk of detecting false positives due to effects 
Fig. 6 Exemplary result of analyzing a T1-weighted MRI data set with 
the current methods. For patient X, cortical thinning was simulated 
in frontal regions, for patient Y in more posterior regions. Method 3 
was used to analyze the data. The emerging p-map indicates where 
cortical thinning likely occurs in each patient. Using the method 
proposed in this text, such maps can be created easily and are 
therefore simple to implement into clinical practice
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of physiological aging. However, progress-monitoring of 
elderly individuals is possible with the current system if 
the individual is compared to its own ranking within the 
control population for each measurement time point. 
Therefore, the tool proposed in this work represents a 
first step of the translation of cortical thickness measures 
into clinical practice.
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